GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sensorion SA (XPAR:ALSEN) » Definitions » Deferred Policy Acquisition Costs

Sensorion (XPAR:ALSEN) Deferred Policy Acquisition Costs


View and export this data going back to 2015. Start your Free Trial

What is Sensorion Deferred Policy Acquisition Costs?

Deferred Policy Acquisition Costs only applies to banks and insurance companies.


Sensorion (XPAR:ALSEN) Business Description

Industry
Traded in Other Exchanges
Address
375, rue du Professeur Joseph Blayac, Montpellier, FRA, 34080
Sensorion SA is a France-based clinical-stage biotech company dedicated to the development of therapies to restore, treat and prevent hearing loss. The company's product is in phase 2 clinical development, SENS-401 (Arazasetron) in Sudden Sensorineural Hearing Loss (SSNHL). SENS-401 is being developed to treat cochlear pathologies.